Literature DB >> 19609730

Dose dependency and reversibility of serotonin-induced valvular heart disease in rats.

Steven Droogmans1, Bram Roosens, Bernard Cosyns, Céline Degaillier, Sophie Hernot, Caroline Weytjens, Christian Garbar, Vicky Caveliers, Miriam Pipeleers-Marichal, Philippe R Franken, Axel Bossuyt, Danny Schoors, Tony Lahoutte, Guy Van Camp.   

Abstract

Serotonergic drugs may lead to valvular heart disease in humans and more recently also in rats. Although clinical data suggest that dose dependency and reversibility after drug cessation might occur, proof of this is lacking. For that purpose, a total of 106 rats were prospectively enrolled: 22 control animals and 7 groups of 12 rats that received daily subcutaneous serotonin injections (5, 10, 20, 30, 40, 50 and 60 mg/kg respectively) for 12 weeks. At 12 weeks, half of the animals of each group were killed for histological analysis, whereas the remaining rats were further followed (without serotonin injections) for an additional 8 weeks. After 12 weeks of serotonin treatment, aortic and mitral regurgitation (AR, MR) were more frequently observed in the high dose groups (>30 mg/kg) compared to controls. Moreover, aortic and mitral valves were also thicker in the high dose groups compared to controls. After 8 weeks free of serotonin injections, AR and MR were no longer significantly higher than controls. Moreover, aortic and mitral valve thickness had normalized, returning to control levels. In conclusion, this study provides evidence for a dose-dependent valvular toxicity of serotonergic drugs, which appears to be reversible after drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609730     DOI: 10.1007/s12012-009-9046-2

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  6 in total

1.  Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness.

Authors:  Kartik Balachandran; Marina A Bakay; Jeanne M Connolly; Xuemei Zhang; Ajit P Yoganathan; Robert J Levy
Journal:  Ann Thorac Surg       Date:  2011-07       Impact factor: 4.330

Review 2.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.

Authors:  Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Pathol       Date:  2020-01-07       Impact factor: 2.185

Review 3.  Serotonin receptors and heart valve disease--it was meant 2B.

Authors:  Joshua D Hutcheson; Vincent Setola; Bryan L Roth; W David Merryman
Journal:  Pharmacol Ther       Date:  2011-04-02       Impact factor: 12.310

4.  Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.

Authors:  S E Cremer; G E Singletary; L H Olsen; K Wallace; J Häggström; I Ljungvall; K Höglund; C A Reynolds; N Pizzinat; M A Oyama
Journal:  J Vet Intern Med       Date:  2014-08-21       Impact factor: 3.333

Review 5.  Serotonin-A Driver of Progressive Heart Valve Disease.

Authors:  Helge Waldum; Alexander Wahba
Journal:  Front Cardiovasc Med       Date:  2022-01-28

6.  Case Report: Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation.

Authors:  Chris G Yedinak; Shirley McCartney; Troy H Dillard; Kevin S Wei; Maria Fleseriu
Journal:  F1000Res       Date:  2014-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.